Terms: = Prostate cancer AND USP8, FLJ34456, 9101, ENSG00000138592, KIAA0055, P40818, MGC129718, UBPY, HumORF8
4 results:
1. The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.
Le Clorennec C; Lazrek Y; Dubreuil O; Larbouret C; Poul MA; Mondon P; Melino G; Pèlegrin A; Chardès T
Oncotarget; 2016 Jun; 7(24):37013-37029. PubMed ID: 27203743
[TBL] [Abstract] [Full Text] [Related]
2. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies.
Guo YZ; Pan L; Du CJ; Ren DQ; Xie XM
Asian Pac J Cancer Prev; 2013; 14(1):243-8. PubMed ID: 23534731
[TBL] [Abstract] [Full Text] [Related]
3. Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy.
van Roermund JG; Hinnen KA; Battermann JJ; Witjes JA; Bosch JL; Kiemeney LA; van Vulpen M
BJU Int; 2010 Jan; 105(1):42-8. PubMed ID: 19519759
[TBL] [Abstract] [Full Text] [Related]
4. Trends in cancer incidence among Singapore Malays: a low-risk population.
Wang H; Seow A; Lee HP
Ann Acad Med Singap; 2004 Jan; 33(1):57-62. PubMed ID: 15008564
[TBL] [Abstract] [Full Text] [Related]
